, Tracking Stock Market Picks
Enter Symbol:
Cyclacel Pharmaceuticals, Inc. (CYCC) [hlAlert]

down 93.05 %

Cyclacel Pharmaceuticals, Inc. (CYCC) rated Buy by Merriman

Posted on: Wednesday,  Oct 28, 2009  8:25 AM ET by Merriman

Merriman rated Buy Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) on 10/28/2009, when the stock price was $7.49. Since
then, Cyclacel Pharmaceuticals, Inc. has lost 93.06% as of 08/27/2015's recent price of $0.52.
If you would have followed this Merriman's recommendation on CYCC, you would have lost 93.05% of your investment in 2129 days.

Cyclacel Pharmaceuticals, Inc. (Cyclacel) is a development-stage biopharmaceutical company engaged in the discovery, development and commercialization of mechanism-targeted drugs to treat human cancers and other serious disorders. The Company markets, directly in the United States, Xclair Cream for radiation dermatitis, and Numoisyn Liquid and Numoisyn Lozenges for xerostomia through its wholly owned subsidiary, ALIGN Pharmaceuticals, LLC (ALIGN). Cyclacel focuses primarily on the development of orally available anticancer agents that target the cell cycle with the aim of slowing the progression or shrinking the size of tumors. The Company has been focusing on the cell cycle since its inception. On January 13, 2009, it announced that the Company began treating patients in a Phase II, open label, single arm, multicenter clinical trial of sapacitabine in patients with non-small cell lung cancer (NSCLC) who have had one prior chemotherapy.

Merriman provides advanced tools for acquiring such information. These tools integrate a combination of cycles, geocosmic signatures and trend analysis patterns in assisting the serious investor in their interpretation of the various financial markets and the general economy. In today's fast paced and seemingly chaotic marketplace, you need the edge that only a broader analysis of human activity can provide.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
10/28/2009 8:25 AM Buy
as of 12/31/2009
1 Week up  53.60 %
1 Month up  73.25 %
3 Months up  39.25 %
1 YTD up  39.25 %

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy